2. Search Result
Search Result
Results for "

lysosomal

" in MedChemExpress (MCE) Product Catalog:

256

Inhibitors & Agonists

1

Screening Libraries

26

Fluorescent Dyes

12

Biochemical Assay Reagents

13

Peptides

6

Inhibitory Antibodies

38

Natural
Products

19

Recombinant Proteins

17

Isotope-Labeled Compounds

9

Antibodies

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15575
    VcMMAE
    Maximum Cited Publications
    92 Publications Verification

    MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE; Vedotin

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
    VcMMAE
  • HY-N1724
    Concanamycin A
    Maximum Cited Publications
    27 Publications Verification

    Antibiotic X 4357B; Folimycin; X 4357B

    		 Proton Pump Bacterial Antibiotic Infection Inflammation/Immunology Cancer
    Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H +-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research - .
    Concanamycin A
  • HY-N2334
    Glycochenodeoxycholic acid
    5 Publications Verification

    Chenodeoxycholylglycine

    		 Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    Glycochenodeoxycholic acid
  • HY-N2334A
    Glycochenodeoxycholic acid sodium salt
    5 Publications Verification

    Chenodeoxycholylglycine sodium salt; Sodium glycochenodeoxycholate

    		 Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    Glycochenodeoxycholic acid sodium salt
  • HY-108462
    ML-SA1
    5+ Cited Publications

    		 Dengue Virus TRP Channel Flavivirus Infection
    ML-SA1, as a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC50 value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral .
    ML-SA1
  • HY-D2449
    DQ-BSA-RED
    2 Publications Verification

    		 Fluorescent Dye Others
    DQ-BSA-Red is a bovine serum albumin labeled with a red fluorescent dye that can be used to detect lysosomal activity. The excitation wavelength and emission wavelength of DQ-BSA-Red are 590 nm and 620 nm, respectively. The BSA molecule in DQ-BSA-Red is labeled with high concentration of red fluorescent dye in multiple sites, which shows high fluorescence self-inhibition. Once DQ-BSA-RED enters the lysosome, DQ-BSA is cleaved by lysosomal proteases, resulting in unquenched and released fluorescent fragments, emitting bright fluorescence. Inactivated lysosomes are unable to degrade the BSA protein and thus have a lower or even no fluorescent signal .
    DQ-BSA-RED
  • HY-118630
    Vacuolin-1
    10+ Cited Publications

    		 PIKfyve Autophagy Cancer
    Vacuolin-1 is a potent and cell-permeable lysosomal exocytosis inhibitor. Vacuolin-1 blocks the Ca 2+-dependent exocytosis of lysosomes and prevents the release of lysosomal content without affecting the process of resealing. vacuolin‐1 is a potent and selective PIKfyve inhibitor and inhibits late‐stage autophagy by impairing lysosomal maturation. Vacuolin-1 can induce vacuole formation and increase the percentage of enucleated cells .
    Vacuolin-1
  • HY-W011063
    Gly-Phe-β-naphthylamide

    		Cathepsin Metabolic Disease
    Gly-Phe-β-naphthylamide is a substrate of Cathepsin C (HY-P2922) and belongs to the lysosomal agonist. Gly-Phe-β-naphthylamide can freely pass through the cell membrane and organelle membrane. Gly-Phe-β-naphthylamide will be specifically hydrolyzed by Cathepsin C, ultimately leading to a permeability lysis when it enters the acidic compartment. Gly-Phe-β-naphthylamide can be used to study lysosomal hydrolysis, lysosomal membrane permeability, and the function of cathepsin C .
    Gly-Phe-β-naphthylamide
  • HY-128892
    EN6
    5 Publications Verification

    		 Autophagy Neurological Disease
    EN6 is a small-molecule in vivo autophagy activator that covalently targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase. EN6-mediated modification of ATP6V1A uncouples v-ATPase from Rag, leading to inhibition of mTORC1 signalling, increased lysosomal acidification, and activation of autophagy. EN6 also scavenges TDP-43 aggregates (causative agents of frontotemporal dementia) in a lysosome-dependent manner .
    EN6
  • HY-P2803
    Beta-glucuronidase (Escherichia coli)
    1 Publications Verification

    		 β-glucuronidase Metabolic Disease
    Beta-glucuronidase is a glycosyl hydrolase that hydrolyzes β-glucuronic acid and sulfate esters in urine and other biological fluids, and then releases β-glucuronate .
    Beta-glucuronidase (Escherichia coli)
  • HY-12855A
    Lys05
    4 Publications Verification

    Lys01 trihydrochloride

    		 Autophagy Cancer
    Lys05 (Lys01 trihydrochloride) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.
    Lys05
  • HY-D1563
    pH Receptor Probe
    1 Publications Verification

    		 Fluorescent Dye Others
    pH Receptor Probe is a pH-sensitive cyanine derivative and a environmental sensitive fluorophore. pH Receptor Probe has a pH-sensitive maximal absorption at 644 nm and emission at 664 nm. pH Receptor Probe has been used as a pH sensor of lysosomal compartments .
    pH Receptor Probe
  • HY-59291
    Levacetylleucine

    N-Acetyl-L-leucine

    		 Amino Acid Derivatives Neurological Disease Metabolic Disease Inflammation/Immunology
    Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention .
    Levacetylleucine
  • HY-33878
    2-PPA

    		Potassium Channel Proton Pump Neurological Disease
    2-PPA is a lysosomal potassium and proton channel TMEM175 pore blocker. 2-PPA binds at a TMEM175 pore site to occlude potassium and proton ion permeation pathways. 2-PPA increases lysosomal macromolecule catabolism, accelerates macropinocytosis. 2-PPA binds to hepatic protein in covalent. 2-PPA can be used for the research of Parkinson's disease .
    2-PPA
  • HY-111621
    DC661
    5+ Cited Publications

    		 Autophagy Apoptosis Cancer
    DC661 is a potent palmitoyl-protein thioesterase 1 (PPT1) inhibitor, inhibits autophagy, and acts as an anti-lysosomal agent. Anti-cancer activity .
    DC661
  • HY-139452
    PFB-FDGlu

    		Glycosidase Others
    PFB-FDGlu is a selective lysosomal Glucocerebrosidase (GCase) substrate, which is metabolised by GCase to yield fluorescein. PFB-FDGlu is cell permeable and can be used with a flow cytometer to measure GCase activity in living cells on a single-cell basis .
    PFB-FDGlu
  • HY-N6779
    Patulin
    4 Publications Verification

    Terinin

    		 Bacterial Apoptosis Autophagy Antibiotic Infection
    Patulin (Terinin) is a mycotoxin produced by fungi including the Aspergillus, Penicillium, and Byssochlamys species, causes chromosome breakage, mutation, teratogenic and cytotoxic. Patulin induces autophagy-dependent apoptosis through lysosomal-mitochondrial axis, and causes DNA damage .
    Patulin
  • HY-162666
    TMEM175 modulator 1

    		Potassium Channel Neurological Disease
    TMEM175 modulator 1 (compound 47) is a TMEM175 modulator.TMEM175 modulator 1 modulates activity of the lysosomal potassium ion channel TMEM175.TMEM175 modulator 1 can be used for the research of parkinson’s disease, dementia, alzheimer’s disease, l-dopa induced dyskinesia .
    TMEM175 modulator 1
  • HY-148189
    Aldometanib
    5+ Cited Publications

    LXY-05-029

    		 Fructose-1,6-bisphosphate aldolase AMPK Metabolic Disease
    Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .
    Aldometanib
  • HY-147976
    Glucocerebrosidase-IN-1

    		Glycosidase Neurological Disease Metabolic Disease
    Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC50 of 29.3 μM and a Ki of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .
    Glucocerebrosidase-IN-1
  • HY-131703
    UGT8-IN-1
    1 Publications Verification

    		 UGT Metabolic Disease
    UGT8-IN-1 is a brain penetrable and orally active inhibitor of ceramide galactosyltransferase enzyme (UGT8). UGT8-IN-1 can be used in the study for lysosomal storage disorders .
    UGT8-IN-1
  • HY-138936
    SSK1
    2 Publications Verification

    		 p38 MAPK Apoptosis Inflammation/Immunology
    SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted proagent attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis .
    SSK1
  • HY-N0866
    20-Deoxyingenol
    5 Publications Verification

    		 Autophagy Inflammation/Immunology
    20-Deoxyingenol, a diterpene, is isolated from the roots of Euphorbia kansui. 20-Deoxyingenol can promote autophagy and lysosomal biogenesis by promoting the nuclear translocation of transcription factor EB (TFEB) in vitro. 20-Deoxyingenol can be used for the research of osteoarthritis (OA) .
    20-Deoxyingenol
  • HY-126306
    Deoxyfuconojirimycin hydrochloride

    		Glycosidase Others
    Deoxyfuconojirimycin hydrochloride is a highly specific α-L-fucosidase inhibitor, with a Ki value of 10 nM against human liver lysosomal α-L-fucosidase and a Ki value of 140 nM against Charonia lampas α-L-fucosidase. Deoxyfuconojirimycin hydrochloride completely inhibits the activity of all soluble α-L-fucosidases in human liver, including multiple post-translationally generated enzyme forms. Deoxyfuconojirimycin hydrochloride exhibits no anti-human immunodeficiency virus activity .
    Deoxyfuconojirimycin hydrochloride
  • HY-161949
    AP-6
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    AP-6 is a selective inhibitor of TMEM175 with activity in modulating lysosomal function. Acute inhibition of TMEM175 by AP-6 increases lysosomal macromolecular catabolism, thereby accelerating macrophage and other digestive processes. AP-6 may be used in Parkinson's disease research .
    AP-6
  • HY-P1759
    N-CBZ-Phe-Arg-AMC

    Z-FR-AMC

    		 Cathepsin Others
    N-CBZ-Phe-Arg-AMC (Z-FR-AMC) is a cathepsin substrate used in assessment activity of lysosomal cathepsin enzymes .
    N-CBZ-Phe-Arg-AMC
  • HY-147354
    TriGalNAc CBz

    		LYTACs Cardiovascular Disease
    TriGalNAc CBz is a GalNAc derivative and tri-GalNAc is an asialoglycoprotein receptor (ASGPR) ligand. TriGalNAc CBz can be used for mRNA drug delivery as well as lysosomal targeted chimerism (LYTAC) studies .
    TriGalNAc CBz
  • HY-103593
    LCL521
    2 Publications Verification

    		 Phospholipase Cancer
    LCL521 is an acid ceramidase (ACDase) inhibitor. LCL521 also inhibits the lysosomal acid sphingomyelinase (ASMase) .
    LCL521
  • HY-P1759B
    N-CBZ-Phe-Arg-AMC TFA

    Z-FR-AMC TFA

    		 Cathepsin Others
    N-CBZ-Phe-Arg-AMC (Z-FR-AMC) TFA is a cathepsin substrate used in assessment activity of lysosomal cathepsin enzymes .
    N-CBZ-Phe-Arg-AMC TFA
  • HY-123058
    Vps34-IN-4

    		PI3K Autophagy Cancer
    Vps34-IN-4 (compound 19) is a potent, selective, and orally active inhibitor of VPS34. Vps34-IN-4 inhibits the autophagy in vivo. Autophagy is a dynamic process that regulates lysosomal-dependent degradation of cellular components .
    Vps34-IN-4
  • HY-107720
    ARL 17477
    1 Publications Verification

    		 NO Synthase Cancer
    ARL-17477 is a dual inhibitor of NOS1and the autophagy-lysosomal system with anticancer activity and can inhibit tumor growth in KRAS-mutated cancers .
    ARL 17477
  • HY-101457
    JZP-430

    		MAGL Metabolic Disease
    JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL) .
    JZP-430
  • HY-42709
    Z-Val-Ala-OH

    Carbobenzoxy-L-valyl-L-alanine

    		 Amino Acid Derivatives Cancer
    Z-Val-Ala-OH is a dipeptide derivative of valine and alanine. Z-Val-Ala-OH undergoes cleavage by cathepsin B and other lysosomal proteases to enable payload release following lysosomal internalization. Z-Val-Ala-OH can be used for the research of antibody-drug conjugate (ADC) development[1] .
    Z-Val-Ala-OH
  • HY-132177
    α-L-Fucosidase, Microorganism
    1 Publications Verification

    EC 3.2.1.51; FUC

    		 Endogenous Metabolite Cancer
    α-L-Fucosidase, Microorganism (EC 3.2.1.51) is an enzyme that catalyzes the chemical reaction. Serum activity of α-L-Fucosidase, Microorganism, a lysosomal enzyme present in all mammalian cells, has been proposed as a marker of hepatocellular carcinoma (HCC) .
    α-L-Fucosidase, Microorganism
  • HY-129411
    Sinbaglustat

    ACT-519276; OGT2378

    		 Glucosylceramide Synthase (GCS) Metabolic Disease
    Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions .
    Sinbaglustat
  • HY-E70181
    Galactosylceramidase

    EC:3.2.1.46; GALC

    		 Ceramidase Others
    Galactosylceramidase involves in lysosomal catabollsm of galactosytceramide. Galactosylceramidase can be used in study Krabbe disease .
    Galactosylceramidase
  • HY-P1759A
    N-CBZ-Phe-Arg-AMC hydrochloride

    Z-FR-AMC hydrochloride

    		 Cathepsin Others
    N-CBZ-Phe-Arg-AMC (Z-FR-AMC) hydrochloride is a cathepsin substrate used in assessment activity of lysosomal cathepsin enzymes .
    N-CBZ-Phe-Arg-AMC hydrochloride
  • HY-137572
    (R)-DOI hydrochloride

    		5-HT Receptor Neurological Disease Inflammation/Immunology
    (R)-DOI hydrochloride is a selective 5HT2A receptor agonist. (R)-DOI hydrochloride has anti-inflammatory, anti-oxidative stress, and lysosomal function-improving effects. (R)-DOI hydrochloride can be used for the researches of inflammation and neurological disease, such as Alzheimer's disease .
    (R)-DOI hydrochloride
  • HY-159625
    WX8
    1 Publications Verification

    Ro 91-4714

    		 PIKfyve Cancer
    WX8 (Ro 91-4714) is an ATP-competitive PIKFYVE inhibitor, with Kd values of 0.9 nM and 340 nM for PIKFYVE and PIP4K2C, respectively. WX8 (Ro 91-4714) inhibits lysosomal fission without effecting homotypic lysosomal fusion. WX8 (Ro 91-4714) is used in the research of autophagy-dependent cancer .
    WX8
  • HY-DY1071
    pH Receptor Probe (solution)

    		Fluorescent Dye Others
    pH Receptor Probe (solution) is a pH-sensitive cyanine derivative and a environmental sensitive fluorophore. pH Receptor Probe has a pH-sensitive maximal absorption at 644 nm and emission at 664 nm. pH Receptor Probe has been used as a pH sensor of lysosomal compartments .
    Solvent and concentration: DMSO: 10 mM
    pH Receptor Probe (solution)
  • HY-129746
    Arylquin 1

    		Apoptosis Cancer
    Arylquin 1, a prostate-apoptosis-response-4 (Par-4) secretagogue, targets vimentin to induce Par-4 secretion. Arylquin 1 induces non-apoptotic cell death in cancer cells through the induction of lysosomal membrane permeabilization (LMP) .
    Arylquin 1
  • HY-153880
    KRAS degrader-1

    		LYTACs Ras Cancer
    KRAS degrader-1 is a potent KRAS degrader. KRAS degrader-1 targets specific proteins for degradation via the autophagy-lysosomal degradation pathway. KRAS degrader-1 is suitable for use in cancer research. (Blue: KRAS G12C-IN-72 (HY-128414); Black: Linker (HY-175587); Pink: 5-Iodoindolin-2-one (HY-76986); Blue + Black: KRAS ligand-Linker Conjugate 7 (HY-175586)) .
    KRAS degrader-1
  • HY-P2922
    Cathepsin C

    		Cathepsin Cancer
    Cathepsin C is a lysosomal cysteine protease essential for catalytic activation of many serine proteases, including proteinase 3 (PR3), neutrophil elastase (NE), cathepsin G (CTSG), granzyme A/B/C, and mast cell chymase .
    Cathepsin C
  • HY-D1632
    4-MU-α-GlcNS sodium

    		Fluorescent Dye Others
    4-MU-α-GlcNS sodium is a fluorogenic substrate of heparin sulphamidase, is desulfurized into 4-MU-α-GlcNH2. 4-MU-α-GlcNH2 can liberate 4-methylumbelliferone (4-MU, fluorescent product) via α-glucosaminidase catalysis, with the emission wavelength maxima of 445-454 nm. 4-MU-α-GlcNS sodium can be used to heparin sulphamidase deficiencies associated with Mucopolisaccaridosis IIIA and other lysosomal disorders researches .
    4-MU-α-GlcNS sodium
  • HY-N2334R
    Glycochenodeoxycholic acid (Standard)

    Chenodeoxycholylglycine (Standard)

    		 Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid (Standard) is the analytical standard of Glycochenodeoxycholic acid. This product is intended for research and analytical applications. Glycochenodeoxycholic acid (Chenodeoxycholylglycine) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC)[1][2][3][4].
    Glycochenodeoxycholic acid (Standard)
  • HY-N2334AR
    Glycochenodeoxycholic acid sodium salt (Standard)

    Chenodeoxycholylglycine sodium salt (Standard); Sodium glycochenodeoxycholate (Standard)

    		 Reference Standards Endogenous Metabolite Apoptosis STAT BCL6 Interleukin Related Caspase Metabolic Disease Cancer
    Glycochenodeoxycholic acid sodium salt (Standard) is the analytical standard of Glycochenodeoxycholic acid sodium salt. This product is intended for research and analytical applications. Glycochenodeoxycholic acid sodium salt (Sodium glycochenodeoxycholate) is a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. Glycochenodeoxycholic acid sodium salt inhibits Autophagosome formation and impairs lysosomal function by inhibiting lysosomal proteolysis and increasing lysosomal pH in human normal liver cells, leading to the Apoptosis of human hepatocyte cells. Glycochenodeoxycholic acid sodium salt induces stemness and chemoresistance via activating STAT3 signaling pathway in hepatocellular carcinoma cells (HCC). Glycochenodeoxycholic acid sodium salt is promising for research in the field of cholestasis desease, hepatocellular carcinoma and primary sclerosing cholangitis (PSC) .
    Glycochenodeoxycholic acid sodium salt (Standard)
  • HY-E70183
    Lysosomal α-Glucosidase

    EC:3.2.1.20; GAA

    		 Biochemical Assay Reagents Others
    Lysosomal α-Glucosidase (EC:3.2.1.20) is a γ-amylase with specificity for glycogen and several natural and synthetic oligoglucosides .
    Lysosomal α-Glucosidase
  • HY-N7526R
    Naphthazarin (Standard)

    DHNQ (Standard); 5,8-Dihydroxy-1,4-naphthoquinone (Standard)

    		 Reference Standards Apoptosis Neurological Disease Cancer
    Naphthazarin (DHNQ) is a naturally occurring compound. Naphthazarin is effective by various cellular mechanisms including oxidative stress, activation of mitochondrial apoptosis-inducing factor (AIF), depolymerization of microtubules, interference with lysosomal function and p53-dependent p21 activation. Naphthazarin triggers apoptosis and has anti-tumor effects .
    Naphthazarin (Standard)
  • HY-123370
    FR-167356

    		Proton Pump Metabolic Disease Cancer
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
    FR-167356
  • HY-P2750
    Cathepsin D
    1 Publications Verification

    CTSD

    		 Biochemical Assay Reagents Cardiovascular Disease Neurological Disease Cancer
    Cathepsin D (CTSD) is a lysosomal aspartic protease encoded by the CTSD gene. Cathepsin D regulates lysosomal protease activity. Loss of Cathepsin D leads to lysosomal dysfunction and the accumulation of various cellular proteins associated with neurodegenerative diseases. Cathepsin D is involved in breast cancer metastasis. Cathepsin D can be used in research on diseases such as breast cancer and stroke .
    Cathepsin D

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: